UroGen Pharma Ltd. Ordinary Shares (URGN) is a publicly traded Healthcare sector company. As of May 21, 2026, URGN trades at $29.96 with a market cap of $1.39B and a P/E ratio of -10.77. URGN moved +6.99% today. Year to date, URGN is +36.56%; over the trailing twelve months it is +300.80%. Its 52-week range spans $3.42 to $32.37. Analyst consensus is strong buy with an average price target of $39.29. Rallies surfaces URGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for URGN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $29.96 |
| Market Cap | $1.39B |
| P/E Ratio | -10.77 |
| EPS | $-2.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.37 |
| 52-Week Low | $3.42 |
| Volume | 7.31K |
| Avg Volume | 0 |
| Revenue (TTM) | $140.49M |
| Net Income | $-133.22M |
| Gross Margin | 89.85% |
7 analysts cover URGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.29.